U.S. FDA flags risk of heart inflammation after Novavax COVID vaccine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Novavax (NVAX) Shares Halted for News Pending Ahead of FDA Panel
June 7, 2022 6:55 AM EDTNovavax (NASDAQ: NVAX) Shares Halted for News Pending Ahead of FDA Panel
UPDATE: Cowen Reiterates $150 PT on Novavax (NVAX), Believes 'briefing documents suggest that the vaccine meets all the requirements for approval '
June 3, 2022 11:23 AM EDT(Updated - June 3, 2022 11:24 AM EDT)
Cowen analyst Georgi Yordanov reiterated an Outperform rating and $150.00 price target on Novavax (NASDAQ: NVAX).
The analyst comments " Overall, we believe the briefing documents suggest that the vaccine meets all the requirements for approval and we expect a positive vote at next week's meeting. As for the timing of a potential approval, the Agency does highlight that Novavax is yet to... More
